» Articles » PMID: 33562741

Tumor Evolution and Therapeutic Choice Seen Through a Prism of Circulating Tumor Cell Genomic Instability

Overview
Journal Cells
Publisher MDPI
Date 2021 Feb 10
PMID 33562741
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor heterogeneity and cell populations with metastatic potential. Although an in-depth molecular investigation is limited by the extremely low CTC count in circulation, significant progress has been made recently in single-cell analytical processes. Indeed, CTC monitoring through molecular and functional characterization may provide an understanding of genomic instability (GI) molecular mechanisms, which contribute to tumor evolution and emergence of resistant clones. In this review, we discuss the sources and consequences of GI seen through single-cell analysis of CTCs in different types of tumors. We present a detailed overview of chromosomal instability (CIN) in CTCs assessed by fluorescence in situ hybridization (FISH), and we reveal utility of CTC single-cell sequencing in identifying copy number alterations (CNA) oncogenic drivers. We highlight the role of CIN in CTC-driven metastatic progression and acquired resistance, and we comment on the technical obstacles and challenges encountered during single CTC analysis. We focus on the DNA damage response and depict DNA-repair-related dynamic biomarkers reported to date in CTCs and their role in predicting response to genotoxic treatment. In summary, the suggested relationship between genomic aberrations in CTCs and prognosis strongly supports the potential utility of GI monitoring in CTCs in clinical risk assessment and therapeutic choice.

Citing Articles

Knowledge-map and research trends of circulating tumor cells in breast cancer: a scientometric analysis.

Shi J, Duan Y Discov Oncol. 2024; 15(1):506.

PMID: 39340703 PMC: 11438760. DOI: 10.1007/s12672-024-01385-3.


Exploring Novel Genome Instability-associated lncRNAs and their Potential Function in Pan-Renal Cell Carcinoma.

Zhu H, Zheng W, Chen H, Chen J, Lin F, Chen S Comb Chem High Throughput Screen. 2023; 27(12):1788-1807.

PMID: 37957851 DOI: 10.2174/0113862073258779231020052115.


Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer.

Manganaro L, Bianco S, Bironzo P, Cipollini F, Colombi D, Cora D Sci Rep. 2023; 13(1):7759.

PMID: 37173325 PMC: 10182023. DOI: 10.1038/s41598-023-33954-x.


Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma.

Li Z, Ma Z, Xue H, Shen R, Qin K, Zhang Y Front Genet. 2022; 13:917150.

PMID: 35873497 PMC: 9305311. DOI: 10.3389/fgene.2022.917150.


Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesmuller L Cancers (Basel). 2022; 14(4).

PMID: 35205744 PMC: 8869884. DOI: 10.3390/cancers14040997.


References
1.
Chebouti I, Kuhlmann J, Buderath P, Weber S, Wimberger P, Bokeloh Y . ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. Oncotarget. 2017; 8(15):24303-24313. PMC: 5421848. DOI: 10.18632/oncotarget.13286. View

2.
Primo L, Teixeira L . DNA replication stress: oncogenes in the spotlight. Genet Mol Biol. 2020; 43(1 suppl 1):e20190138. PMC: 7197996. DOI: 10.1590/1678-4685GMB-2019-0138. View

3.
Mullard A . Can innate immune system targets turn up the heat on 'cold' tumours?. Nat Rev Drug Discov. 2017; 17(1):3-5. DOI: 10.1038/nrd.2017.264. View

4.
Carter L, Rothwell D, Mesquita B, Smowton C, Leong H, Fernandez-Gutierrez F . Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2016; 23(1):114-119. DOI: 10.1038/nm.4239. View

5.
Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A . Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 2014; 105(8):1002-7. PMC: 4317860. DOI: 10.1111/cas.12453. View